CN112585164A - 用于治疗癌症的、lif抑制剂和pd-1轴抑制剂的组合 - Google Patents

用于治疗癌症的、lif抑制剂和pd-1轴抑制剂的组合 Download PDF

Info

Publication number
CN112585164A
CN112585164A CN201980038348.0A CN201980038348A CN112585164A CN 112585164 A CN112585164 A CN 112585164A CN 201980038348 A CN201980038348 A CN 201980038348A CN 112585164 A CN112585164 A CN 112585164A
Authority
CN
China
Prior art keywords
pdl
amino acid
acid sequence
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980038348.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·塞奥内苏亚雷斯
J·阿尼多富尔盖拉
J·弗兰森
R·M·哈勒特
M·帕斯夸尔加西亚
E·邦菲尔泰克西多尔
E·普拉纳斯里戈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
MedImmune Ltd
Original Assignee
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron, MedImmune Ltd filed Critical Institucio Catalana de Recerca i Estudis Avancats ICREA
Publication of CN112585164A publication Critical patent/CN112585164A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980038348.0A 2018-04-12 2019-04-11 用于治疗癌症的、lif抑制剂和pd-1轴抑制剂的组合 Pending CN112585164A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18382248 2018-04-12
EP18382248.5 2018-04-12
EP18382326 2018-05-14
EP18382326.9 2018-05-14
EP18382360.8 2018-05-25
EP18382360 2018-05-25
EP19382132 2019-02-22
EP19382132.9 2019-02-22
PCT/IB2019/000423 WO2019197903A1 (en) 2018-04-12 2019-04-11 Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer

Publications (1)

Publication Number Publication Date
CN112585164A true CN112585164A (zh) 2021-03-30

Family

ID=67060425

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980038348.0A Pending CN112585164A (zh) 2018-04-12 2019-04-11 用于治疗癌症的、lif抑制剂和pd-1轴抑制剂的组合

Country Status (11)

Country Link
US (1) US20210130453A1 (enExample)
EP (1) EP3774895A1 (enExample)
JP (2) JP7423598B2 (enExample)
KR (1) KR20210021287A (enExample)
CN (1) CN112585164A (enExample)
AU (1) AU2019251289B2 (enExample)
CA (1) CA3096779A1 (enExample)
IL (1) IL277918A (enExample)
MA (1) MA52231A (enExample)
SG (1) SG11202009966SA (enExample)
WO (1) WO2019197903A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017381585B2 (en) * 2016-12-19 2025-02-13 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Antibodies against LIF and uses thereof
KR20210008514A (ko) * 2018-05-14 2021-01-22 메디뮨 리미티드 Lif에 대한 항체 및 이의 투여 형태
EP4069736A1 (en) * 2019-12-04 2022-10-12 MedImmune Limited Antibodies against lif and uses thereof
JP7796032B2 (ja) * 2020-03-11 2026-01-08 パーデュー・リサーチ・ファウンデーション 免疫調節活性を持つ化合物およびその治療的使用
WO2023159152A2 (en) * 2022-02-17 2023-08-24 Immune-Onc Therapeutics, Inc. Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
WO2016040657A1 (en) 2014-09-10 2016-03-17 The Regents Of The University Of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
AU2017381585B2 (en) 2016-12-19 2025-02-13 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Antibodies against LIF and uses thereof
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation

Also Published As

Publication number Publication date
JP7423598B2 (ja) 2024-01-29
WO2019197903A8 (en) 2020-02-20
CA3096779A1 (en) 2019-10-17
AU2019251289B2 (en) 2024-01-18
IL277918A (en) 2020-11-30
EP3774895A1 (en) 2021-02-17
WO2019197903A1 (en) 2019-10-17
JP2024054138A (ja) 2024-04-16
US20210130453A1 (en) 2021-05-06
JP2021521274A (ja) 2021-08-26
AU2019251289A1 (en) 2020-11-26
KR20210021287A (ko) 2021-02-25
MA52231A (fr) 2021-02-17
SG11202009966SA (en) 2020-11-27
AU2019251289A8 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
JP7540994B2 (ja) 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用
JP6552621B2 (ja) 抗ｐｄ−１抗体およびその使用方法
AU2015316991B2 (en) Neutralization of inhibitory pathways in lymphocytes
AU2019251289B2 (en) Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer
JP7459173B2 (ja) Ｌｉｆに対する抗体及びその使用
CN108064169A (zh) 抗体、用途和方法
KR20200074993A (ko) 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체
CN112638941A (zh) 针对lif的抗体及其剂量形式
JP7520727B2 (ja) 癌を有する個人における抗ｌｉｆ抗体治療に対する反応を向上させるための方法
HK40049059A (en) Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
EA047583B1 (ru) Комбинация ингибиторов lif и ингибиторов оси pd-1 для применения в лечении рака
HK40051950A (zh) 用於改善患有癌症的个体对抗lif抗体治疗的反应的方法
HK40042216A (en) Antibodies against lif and dosage forms thereof
EA044914B1 (ru) Способы улучшения ответа на лечение с помощью антитела к lif у индивидуумов, страдающих от рака
EA049383B1 (ru) Способы улучшения ответа на лечение с помощью антитела к lif у индивидуумов, страдающих от рака
HK40056275A (en) Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
CN112955178A (zh) 用于治疗癌症的、lif抑制剂和基于铂的抗肿瘤剂的组合
EA049507B1 (ru) ВЫСОКОАФФИННЫЕ, СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ ИЗОФОРМЫ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40049059

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210330